Investigational drug · Phase 3
MPSV4
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Meningococcal Meningitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "MPSV4"
First trial start
2024
Mar 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MPSV4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Meningococcal Meningitis
Largest trials
Live from ClinicalTrials.gov: studies naming "MPSV4" as an intervention, largest first.
Neuroganics LLCIndustry
NCT05095844 · 100,000 participants (planned) · Start Mar 15, 2022 · Primary completion Apr 1, 2024
Drug: vaccinated · For: COVID-19; Vaccine Adverse Reaction; Vaccine Reaction and 10 more
Sites: Northglenn, Colorado
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year OldsPivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT06700148 · 840 participants · Start Dec 14, 2024 · Primary completion Feb 19, 2025
Drug: MCV4; MPSV4 · For: Meningococcal Meningitis
Sites: Dengfeng, China; Kaifeng, China
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year OldsPivotal-lookingActive, not recruiting
CanSino Biologics Inc.Industry
NCT06226714 · 840 participants · Start Mar 1, 2024 · Primary completion Sep 26, 2024
Drug: MCV4; MPSV4 · For: Meningococcal Meningitis
Sites: Chongqing, China · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Characterization and vaccine-induced immunogenicity of a re-emerging Neisseria meningitidis serogroup Y in Tianjin, China.
Zhang G, Li W, Sui X, et al. · Vaccine 2026
- Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.
Coudeville L, Bertrand-Gerentes I, Zocchetti C, et al. · Sci Rep 2025
- Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ࣙ56 years of age.
Robertson CA, Jacqmein J, Selmani A, et al. · Hum Vaccin Immunother 2024
- Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ࣙ59 years: A phase III randomized study.
Robertson CA, Jacqmein J, Selmani A, et al. · Hum Vaccin Immunother 2023
- Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
Neveu D, Mallett Moore T, Zambrano B, et al. · Infect Dis Ther 2023
- Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ࣙ56-year-olds: A Phase III randomized study.
Esteves-Jaramillo A, Koehler T, Jeanfreau R, et al. · Vaccine 2020
Also in development for Meningococcal Meningitis
- MCV4Phase 32 trials
CanSino Biologics Inc. · Meningococcal Meningitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.